The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity, and scientific rigor for all Continuing Medical Education (CME) activities.
In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME-defined ineligible companies. All disclosures are reviewed to identify relevant financial relationships, and any conflicts of interest are mitigated before the individual can assume their role in the activity.
All disclosures will be available to participants via the conference app and on the conference website.
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the “other activity” (a live conference offered in a hybrid format including recorded virtual participation) format for this educational activity for a maximum of 14.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).
Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.
International CPD Credit Reciprocity Agreements
Canada:
The Royal College will recognize the number of participation hours as MOC Program Section 1 accredited group learning credits for group learning activities developed by Accreditation Council for Continuing Medical Education (ACCME)-accredited physician organizations (university, academy, specialty society, hospital department, etc.) that are held within and outside of Canada. Agreement dates: November 1, 2019, to December 31, 2025.
European Union:
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Qatar:
The American Medical Association (AMA) and the Department of Healthcare Professions–Accreditation Section (DHP-AS), Ministry of Public Health–Qatar have renewed their CME agreement under which select activities approved for AMA PRA Category 1 Credit™ are eligible for conversion of the hours of participation to Department of Healthcare Professions Continuing Professional Development (DHP-CPD) credit. This agreement is in place through Dec. 31, 2026.
Off-Label Disclosure
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of the IASLC or any company that provided commercial support for this activity.
Goal & Purpose at NACLC 2023
The IASLC North America Conference on Lung Cancer (NACLC) is a premier event featuring dynamic education sessions, illuminating oral abstracts, and engaging poster presentations. Attendees will explore diverse topics like screening and prevention strategies and disparities, screening methodologies, and disparities influencing screening. Additionally, the conference delves into intricate aspects of surgical management, advanced radiation therapy techniques, breakthroughs in novel therapeutics, and recent advancements in diagnostics and thoracic cancer pathology. NACLC fosters robust networking opportunities, offers insightful case studies, and facilitates direct interaction with leading experts, pushing the boundaries of knowledge and collaboration.
Target Audience at NACLC 2023
The IASLC 2023 North America Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer and other thoracic malignancies, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, physician assistants, and nurses. The conference is also designed to provide a forum for lung cancer patients and patient advocates to receive education and share their perspectives with the lung cancer community.
Learning Objectives at NACLC 2023
At the conclusion of this activity, participants will be able to:
- Apply evidence-based recommendations and clinical practice guidelines to diagnose and treat patients with lung cancer and other thoracic malignancies.
- Describe scientific advances in lung cancer and other thoracic malignancies.
- Synthesize research from clinical trials and translational studies to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
- Advocate for lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, and implementing early screening.
- Engage and empower patients to become active participants in their treatment.
Official Language at NACLC 2023
The official language of the IASLC 2023 North America Conference on Lung Cancer is English.
Disclaimer
The information presented at the IASLC 202 North America Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity, and scientific rigor for all Continuing Medical Education (CME) activities.
In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME-defined ineligible companies. All disclosures are reviewed to identify relevant financial relationships, and any conflicts of interest are mitigated before the individual can assume their role in the activity.
All disclosures will be available to participants via the conference app and on the conference website.
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the “other activity” (a live conference offered in a hybrid format including recorded virtual participation) format for this educational activity for a maximum of 14.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).
Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.
International CPD Credit Reciprocity Agreements
Canada:
The Royal College will recognize the number of participation hours as MOC Program Section 1 accredited group learning credits for group learning activities developed by Accreditation Council for Continuing Medical Education (ACCME)-accredited physician organizations (university, academy, specialty society, hospital department, etc.) that are held within and outside of Canada. Agreement dates: November 1, 2019, to December 31, 2025.
European Union:
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Qatar:
The American Medical Association (AMA) and the Department of Healthcare Professions–Accreditation Section (DHP-AS), Ministry of Public Health–Qatar have renewed their CME agreement under which select activities approved for AMA PRA Category 1 Credit™ are eligible for conversion of the hours of participation to Department of Healthcare Professions Continuing Professional Development (DHP-CPD) credit. This agreement is in place through Dec. 31, 2026.
Off-Label Disclosure
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of the IASLC or any company that provided commercial support for this activity.
Goal & Purpose at NACLC 2023
The IASLC North America Conference on Lung Cancer (NACLC) is a premier event featuring dynamic education sessions, illuminating oral abstracts, and engaging poster presentations. Attendees will explore diverse topics like screening and prevention strategies and disparities, screening methodologies, and disparities influencing screening. Additionally, the conference delves into intricate aspects of surgical management, advanced radiation therapy techniques, breakthroughs in novel therapeutics, and recent advancements in diagnostics and thoracic cancer pathology. NACLC fosters robust networking opportunities, offers insightful case studies, and facilitates direct interaction with leading experts, pushing the boundaries of knowledge and collaboration.
Target Audience at NACLC 2023
The IASLC 2023 North America Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer and other thoracic malignancies, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, physician assistants, and nurses. The conference is also designed to provide a forum for lung cancer patients and patient advocates to receive education and share their perspectives with the lung cancer community.
Learning Objectives at NACLC 2023
At the conclusion of this activity, participants will be able to:
- Apply evidence-based recommendations and clinical practice guidelines to diagnose and treat patients with lung cancer and other thoracic malignancies.
- Describe scientific advances in lung cancer and other thoracic malignancies.
- Synthesize research from clinical trials and translational studies to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
- Advocate for lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, and implementing early screening.
- Engage and empower patients to become active participants in their treatment.
Official Language at NACLC 2023
The official language of the IASLC 2023 North America Conference on Lung Cancer is English.
Disclaimer
The information presented at the IASLC 202 North America Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.